Identification of Potential PBP2a Inhibitors Against Methicillin‐Resistant Staphylococcus aureus via Drug Repurposing and Combination Therapy
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70088 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2025. Written by Fangfang Jiao and 6 co-authors. Institution: Centre in Artificial Intelligence Driven Drug Discovery, Applied Sciences, Macao Polytechnic University, Macao, China. Major MEDLINE topics: Methicillin-Resistant Staphylococcus aureus, Penicillin-Binding Proteins, Drug Repositioning, Anti-Bacterial Agents. Cited 2 times so far (Crossref); 49 references. Funded by: Macao Polytechnic University Internal Grant [RP/CAI-01/2022].
Abstract (original language)
Methicillin‐resistant Staphylococcus aureus (MRSA) achieves high‐level resistance against β‐lactam antibiotics through the expression of penicillin‐binding protein 2a (PBP2a), which features a closed active site that impedes antibiotic binding. Herein, we implemented a strategy that combines drug repurposing with synergistic therapy to identify potential inhibitors targeting PBP2a's allosteric site from an FDA‐approved drug database. Initially, retrospective verifications were conducted, employing different Glide docking methods (HTVS, SP, and XP) and two representative PBP2a structures. The combination of Glide SP and one representative PBP2a conformation showed the highest efficacy in identifying active compounds. The optimized parameters were then utilized to screen FDA‐approved drugs, and 15 compounds were shortlisted for potential combination therapy with cefazolin, an ineffective cephalosporin against MRSA. Through biological assays—checkerboard, time‐kill assays, and live/dead bacterial staining—we discovered that four compounds exhibited robust bactericidal activity (FICI < 0.5) compared to both untreated control and monotherapy with cefazolin alone. Scanning electron microscopy (SEM) confirmed that while cefazolin alone did not cause visible damage to MRSA cells, the combination treatment markedly induced cell lysis. Additional MM‐GBSA studies underscored the strong binding affinity of mitoxantrone to the allosteric site. These findings introduce a combination therapy approach that potentially restores MRSA's susceptibility to β‐lactam antibiotics.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre in Artificial Intelligence Driven Drug Discovery, Applied Sciences, Macao Polytechnic University, Macao, China.
- Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
- College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
- College of Life Sciences, Nanjing Agricultural University, Nanjing, China.
- Engineering Research Centre of Applied Technology on Machine Translation and Artificial Intelligence, Macao Polytechnic University, Macao, China.
Funding
- Macao Polytechnic University Internal Grant [RP/CAI-01/2022]
Cite
APA
Jiao, F., Wang, P., Zeng, D., Bao, Y., Zhang, Y., Tao, J., & Guo, J. (2025). Identification of Potential PBP2a Inhibitors Against Methicillin‐Resistant Staphylococcus aureus via Drug Repurposing and Combination Therapy. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70088
Vancouver
Jiao F, Wang P, Zeng D, Bao Y, Zhang Y, Tao J, et al. Identification of Potential PBP2a Inhibitors Against Methicillin‐Resistant Staphylococcus aureus via Drug Repurposing and Combination Therapy. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70088
BibTeX
@article{Jiao2025,
author = {Jiao, Fangfang and Wang, Pinkai and Zeng, Derong and Bao, Yiqiong and Zhang, Yan and Tao, Jun and Guo, Jingjing},
title = {Identification of Potential PBP2a Inhibitors Against Methicillin‐Resistant Staphylococcus aureus via Drug Repurposing and Combination Therapy},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70088}
}
EUVIMED